Grünenthal Acquires Stivarga Oncology Drug for $375M

In a significant move to bolster its oncology portfolio, German pharmaceutical firm Grünenthal has entered into an agreement to acquire the cancer treatment Stivarga® from Bayer AG. The transaction, valued at up to €375 million (approximately $375 million USD), underscores Grünenthal's strategic focus on expanding its presence in established, high-need therapeutic areas.

Stivarga® (regorafenib) is an oral kinase inhibitor with a proven track record in treating advanced forms of colorectal cancer, gastrointestinal stromal tumors (GIST), and hepatocellular carcinoma. The drug, approved in over 90 global markets, represents a valuable addition to Grünenthal's existing therapeutic offerings, particularly in its core area of pain management and related diseases, where it aims to leverage its commercial infrastructure.

This acquisition aligns with Grünenthal's broader strategy of acquiring mature medicines that address clear medical requirements and possess strong growth potential. The company has a history of successful M&A activity, having invested approximately €2.6 billion in strategic acquisitions since 2017. These investments have demonstrably enhanced profitability and provided capital to fuel its innovative research pipeline. Notable past acquisitions include global rights to Nebido™, European rights to Crestor™ and Nexium™, and the US company Valinor Pharma.

The deal is anticipated to close by the end of 2026 or early 2027, pending regulatory approvals. Grünenthal projects that Stivarga® will contribute positively to its consolidated EBITDA, estimating an impact of up to €100 million for the fiscal year 2027, assuming full-year consolidation and timely closing. This financial uplift is expected to be immediate, reflecting the drug's established market position and revenue generation capabilities.

The market for oncology therapeutics continues to be a dynamic and highly competitive space. With an estimated global oncology market size projected to reach hundreds of billions of dollars in the coming years, driven by advancements in targeted therapies and immunotherapies, strategic acquisitions like this are crucial for established players to maintain and expand market share. Stivarga®'s established efficacy in specific patient populations, particularly those who have exhausted other treatment options, positions it well within this competitive landscape.

Grünenthal's CEO, Gabriel Baertschi, emphasized the strategic fit of Stivarga®, stating, “This acquisition is a strong strategic fit for Grünenthal and reflects our disciplined M&A strategy of acquiring established medicines that address clear and ongoing medical needs and create long-term value.” He further highlighted the opportunity to maximize the drug's value through Grünenthal's commercial and operational expertise, supporting the company's long-term growth trajectory.

The acquisition comes as Stivarga® faces upcoming patent expiries, with loss of exclusivity anticipated in the European Union around 2029 and in the United States by 2030. This timing allows Grünenthal to capitalize on the drug's existing market presence while planning for potential lifecycle management strategies and the integration of the asset into its broader commercial operations.